SCHEMBL15200217

SCHEMBL15200217

Cc1ccc(OC(=O)c2cccs2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 11/20 0.71
MAPT P10636 4/20 0.71
L3MBTL1 Q9Y468 2/20 0.69
HPGD P15428 3/20 0.66
ALDH1A1 P00352 3/20 0.66
PLA2G1B P04054 2/20 0.66
ATG4B Q9Y4P1 2/20 0.66
TSHR P16473 2/20 0.66
TDP1 Q9NUW8 3/20 0.61
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
TP53 P04637 1/20 0.57
NFKB1 P19838 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
KDM4E B2RXH2 3/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C19 P33261 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4810433 0.84 KMT2A (0.68) KMT2AMAPTL3MBTL1HPGDALDH1A1
SCHEMBL27364435 0.83 KMT2A (0.67) KMT2AMAPTL3MBTL1HPGDALDH1A1
SCHEMBL27555836 0.83 KMT2A (0.67) KMT2AMAPTL3MBTL1HPGDALDH1A1
SCHEMBL5710377 0.83 KMT2A (0.67) KMT2AMAPTL3MBTL1HPGDALDH1A1
Iodide SCHEMBL30758523 0.82 KMT2A (0.66) KMT2AMAPTL3MBTL1HPGDALDH1A1
SCHEMBL15200218 0.82 KMT2A (0.61) KMT2AMAPTL3MBTL1HPGDALDH1A1
SCHEMBL12768195 0.82 KMT2A (0.66) KMT2AMAPTL3MBTL1HPGDALDH1A1
SCHEMBL8157515 0.81 KMT2A (0.49) KMT2AMAPTL3MBTL1HPGDALDH1A1
SCHEMBL15009623 0.80 KMT2A (0.63) KMT2AMAPTL3MBTL1HPGDALDH1A1
SCHEMBL10530079 0.80 KMT2A (1.00) KMT2AMAPTL3MBTL1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10548911-B2 Small molecule anti-scarring agents UNIVERSITY OF ROCHESTER (US) 2020-02-04 US disclosed
US-20170216332-A1 SMALL MOLECULE ANTI-SCARRING AGENTS UNIVERSITY OF ROCHESTER (US) 2017-08-03 US disclosed
US-8962244-B2 Compounds for modulating RNA binding proteins and uses therefor UNIVERSITY OF MASSACHUSETTS (US) 2015-02-24 US disclosed
US-20130217685-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR UNIVERSITY OF MASSACHUSETTS (US) 2013-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217685-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR TIA1, ZFP3, RBM3 KMT2A 3013/4885MAPT 4038/4885L3MBTL1 63/4885
US-20170216332-A1 SMALL MOLECULE ANTI-SCARRING AGENTS COLGALT1, MMP1, FIBP KMT2A 3498/4885MAPT 4802/4885L3MBTL1 867/4885
US-10548911-B2 Small molecule anti-scarring agents COLGALT1, MMP1, FIBP KMT2A 3498/4885MAPT 4802/4885L3MBTL1 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.